Back to Search
Start Over
P.046 Real-world survival effectiveness of edaravone in amyotrophic lateral sclerosis: a propensity score weighted, registry-based, Canada-wide cohort study
- Source :
- The Canadian Journal of Neurological Sciences; June 2023, Vol. 50 Issue: Supplement 2 pS70-S70, 1p
- Publication Year :
- 2023
-
Abstract
- Background: ALS is a progressive neurodegenerative disease without a cure and limited treatment options. Edaravone, a free radical scavenger, was shown to slow disease progression in a select group of patients with ALS over 6 months; however, the effect on survival was not investigated in randomized trials. The objective of this study is to describe real-world survival effectiveness over a longer timeframe. Methods: This retrospective cohort study included patients with ALS across Canada with symptom onset up to three years. Those with a minimum 6-month edaravone exposure between 2017 and 2022 were enrolled in the interventional arm, and those without formed the control arm. The primary outcome of tracheostomy-free survival was compared between the two groups, accounting for age, sex, ALS-disease progression rate, disease duration, pulmonary vital capacity, bulbar ALS-onset, and presence of frontotemporal dementia or C9ORF72 mutation using inverse propensity treatment weights. Results: 182 patients with mean ± SD age 60±11 years were enrolled in the edaravone arm and 860 in the control arm (mean ± SD age 63±12 years). Mean ± SD time from onset to edaravone initiation was 18±10 months. Tracheostomy-free survival will be calculated. Conclusions: This study will provide evidence for edaravone effectiveness on tracheostomy-free survival in patients with ALS.
Details
- Language :
- English
- ISSN :
- 03171671
- Volume :
- 50
- Issue :
- Supplement 2
- Database :
- Supplemental Index
- Journal :
- The Canadian Journal of Neurological Sciences
- Publication Type :
- Periodical
- Accession number :
- ejs63218208
- Full Text :
- https://doi.org/10.1017/cjn.2023.150